GU Cancers 2019 | OCUU-CRPC trial: enzalutamide vs. flutamide for CRPC after bicalutamide

Taro Iguchi, MD, PhD, of the Osaka City University, Osaka, Japan, discusses the results of the Phase II OCUU-CRPC study (NCT02346578) investigating the comparative efficacy of enzalutamide vs. flutamide in castration-resistant prostate cancer (CRPC) patients previously treated with combined androgen blockade therapy with bicalutamide. Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Iguchi highlights the promising clinical outcomes in patients treated with enzalutamide, and further gives an overview of the future research focuses for the use of enzalutamide in CRPC treatment.